Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00165763
Status:
COMPLETED
Last Update Posted:
2012-05-04
First Post:
2005-09-12
Brief Title:
Efficacy and Safety of Donepezil Hydrochloride Aricept in Vascular Dementia
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
An Open Label Study on the Efficacy and Safety of Donepezil Hydrochloride Aricept in Vascular Dementia
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to examine the efficacy and safety of cholinesterase inhibitor donepezil hydrochloride Aricept in patients with vascular dementia VaD
Detailed Description:
Vascular dementia is a significant cause of intellectual and functional impairment in young patients consequent to cerebrovascular disease Post-mortem studies show that VaD patients have a cholinergic deficiency like in Alzheimers disease AD Cholinesterase inhibitors are now standard treatment for mild to moderate AD This study aims to determine if donepezil a cholinesterase inhibitor would benefit patients with VaD by decreasing their scores in the VaDAS-cog and improvement in their CIBIC rating over a period of 24-weeks treatment Adverse events will also be monitored
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None